格隆汇8月29日丨心通医疗-B(02160.HK)发布公告，截至2025年6月30日止六个月，集团录得收入人民币2.291亿元，同比增加2.7%，主要是由于报告期内，VitaFlow Liberty®及Alwide®Plus在全球商业化的持续推进，促进了集团的海外收入较2024年同期快速增长235.3%。此外，于报告期内，集团的AnchorMan®左心耳封堵系统及AnchorMan®左心耳导引系统在中国的商业化进展稳步推进，且随后在欧洲实现商业化，亦为集团带来新增收入贡献。
报告期内，集团录得净亏损人民币220万元，较截至2024年6月30日止六个月的亏损人民币5780万元显著减少，该减少主要是由于(i)收入及毛利稳定增长；(ii)通过持续优化资源配置、积极管控各项费用等措施进一步提升运营效率；及(iii)集团的联营公司4C Medical完成D轮融资后，视作出售其股权所产生的收益。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.